BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29393493)

  • 1. Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Zhong A; Zhang H; Xie S; Deng M; Zheng H; Wang Y; Chen M; Lu R; Guo L
    Oncol Rep; 2018 Apr; 39(4):1747-1756. PubMed ID: 29393493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
    Choi YE; Battelli C; Watson J; Liu J; Curtis J; Morse AN; Matulonis UA; Chowdhury D; Konstantinopoulos PA
    Oncotarget; 2014 May; 5(9):2678-87. PubMed ID: 24798692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Ratner ES; Zhu YL; Penketh PG; Berenblum J; Whicker ME; Huang PH; Lee Y; Ishiguro K; Zhu R; Sartorelli AC; Lin ZP
    Br J Cancer; 2016 Mar; 114(7):777-86. PubMed ID: 26964031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
    Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
    Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway.
    Wu F; Chen WJ; Yan L; Tan GQ; Li WT; Zhu XJ; Ge XC; Liu JW; Wang BL
    Cancer Med; 2016 Feb; 5(2):370-85. PubMed ID: 26714930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUS81 Inhibition Increases the Sensitivity to Therapy Effect in Epithelial Ovarian Cancer via Regulating CyclinB Pathway.
    Zhong A; Zheng H; Zhang H; Sun J; Shen J; Deng M; Chen M; Lu R; Guo L
    J Cancer; 2019; 10(10):2276-2287. PubMed ID: 31258731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
    Zhang W; Wu FX; Wang Q; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
    Wang H; Zhu L; Gao J; Hu Z; Lin B
    Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
    Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
    J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
    Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.